The Drug Enforcement Administration (DEA) announced on Wednesday its intention to classify the psychoactive compound 7-hydroxymitragynine (7-OH) and three related substances as Schedule I drugs. This classification places these substances in the same category as heroin and LSD, indicating they have no accepted medical use and a high potential for abuse.
Details of the DEA's Decision on 7-OH
On October 25, 2023, the DEA revealed its plan to impose a temporary ban on products containing 7-OH. This decision comes amid growing concerns regarding the safety and potential for addiction associated with kratom and its derivatives. The agency has stated that this classification will help regulate these substances more effectively.
The move to ban 7-OH reflects broader efforts to address the opioid crisis in the United States, where synthetic drugs have posed significant health risks. The DEA aims to prevent the misuse of these compounds, which have gained popularity as alternatives to traditional opioids.
Implications of the Schedule I Classification
Classifying 7-OH as Schedule I means that it will be subject to strict regulations. This includes prohibiting its manufacture, distribution, and possession. The DEA believes this action is necessary to protect public health, particularly as the opioid epidemic continues to impact communities nationwide.
